Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAEL-101 in Mayo Stage IIIb AL Amyloidosis
NCT04504825Phase 3Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Aug 2020
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 3 trial of anselamimab in amyloid light chain amyloidosis, sponsored by Alexion Pharmaceuticals. Started Aug 2020; status: active, not recruiting.
02
Drugs
anselamimab
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT04504825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04504825.